Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast CancerW. Fraser Symmans, Smita Asare, Xiuzhen Duan et al.|JAMA Oncology|2021Cited by 110
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialMarie Osdoit, Rita A. Mukhtar, Christina Yau et al.|JAMA Surgery|2022Cited by 22
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant ChemotherapySunati Sahoo, Idris Tolgay Ocal, Gregor Krings et al.|Archives of Pathology & Laboratory Medicine|2022Cited by 16
Abstract P6-10-02: Assessing biomarkers to inform treatment de-escalation: Mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TrialSara J. Venters, W. Fraser Symmans, Denise M. Wolf et al.|Cancer Research|2020Cited by 7
Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpointsChristina Yau, Laura J. Esserman, Angela DeMichele et al.|Cancer Research|2020Cited by 2